Alloy Therapeutics, with a valuation of $450 million, is raising funds on OurCrowd through Reg D 506(c) raise. The company has developed a platform that enables collaboration among scientists and democratizes access to foundational drug discovery platforms. The aim of the business is to make drug discovery and creation easier and more efficient. Alloy Therapeutics empowers drug discovery across six biologic modalities, including antibodies, TCRS, genetic medicines, peptides, cell therapies, and delivery. Errik Anderson founded Alloy Therapeutics in 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,120,000. The campaign proceeds will be used for growth and expansion.